Ovarian Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - About This PDQ Summary
About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current
Ovarian Germ Cell Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of ovarian germ cell tumors. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus
Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Option Overview
There are different types of treatment for patients with ovarian low malignant potential tumor. Different types of treatment are available for patients with ovarian low malignant potential tumor. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer, tumors, and related conditions. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.Two types of standard treatment are used: SurgeryThe type of surgery (removing the tumor in an operation) depends on the size and spread of the tumor and the woman's plans for having children. Surgery may include the
Ovarian Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - What is prevention?
WebMD discusses methods of preventing ovarian cancer.
Ovarian Germ Cell Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage I Ovarian Germ Cell Tumors
DysgerminomasStandard treatment options:Unilateral salpingo-oophorectomy with or without lymphangiography or computed tomography (CT).Unilateral salpingo-oophorectomy followed by observation.Unilateral salpingo-oophorectomy with adjuvant radiation therapy or chemotherapy.For patients with stage I dysgerminoma, unilateral salpingo-oophorectomy conserving the uterus and opposite ovary is accepted treatment of the younger patient who wants to preserve fertility or a pregnancy. Postoperative lymphangiography or CT is indicated before treatment decisions are made for patients who have not had careful surgical and pathological examination of pelvic and para-aortic lymph nodes during surgery. (Refer to the PDQ summary on Sexuality and Reproductive Issues for more information on fertility.)Patients who have been completely staged and have stage IA tumors may be observed carefully after surgery without adjuvant treatment. About 15% to 25% of these patients will relapse, but they can be treated
Ovarian Epithelial Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent or Persistent Ovarian Epithelial Cancer Treatment
Overall, approximately 80% of patients diagnosed with ovarian epithelial cancer will relapse after first-line platinum-based and taxane-based chemotherapy and may benefit from subsequent therapies. Early detection of persistent disease by second-look laparotomies after completing first-line treatment is no longer practiced; when the outcomes in the 50% of institutions practicing such procedures were informally compared with the outcomes in those institutions not using such procedures, additional lack of support for them grew, as was found in the case for patients entered in GOG-0158. However, the practice of close follow-up of patients completing treatment by serial CA 125s at intervals of 1 to 3 months was nearly universally adopted. In patients who are in clinical complete remission, increases in CA 125 from their initial treatment represent the most common method to detect disease that will eventually relapse clinically. A trial by the Medical Research
Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (07 / 09 / 2012)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Stage Information for Ovarian Low Malignant Potential Tumors Updated staging information for 2010 (cited FIGO Committee on Gynecologic Oncology and Edge et al. as references 1 and 2, respectively).This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Ovarian Germ Cell Tumors Treatment (PDQ®): Treatment - Patient Information [NCI] - General Information About Ovarian Germ Cell Tumors
Ovarian germ cell tumor is a disease in which malignant (cancer) cells form in the germ (egg) cells of the ovary. Germ cell tumors begin in the reproductive cells (egg or sperm) of the body. Ovarian germ cell tumors usually occur in teenage girls or young women and most often affect just one ovary. The ovaries are a pair of organs in the female reproductive system. They are located in the ...
Ovarian Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Ovarian Cancer Screening
Tests are used to screen for different types of cancer.Some screening tests are used because they have been shown to be helpful both in finding cancers early and in decreasing the chance of dying from these cancers. Other tests are used because they have been shown to find cancer in some people; however, it has not been proven in clinical trials that use of these tests will decrease the risk of dying from cancer. Scientists study screening tests to find those with the fewest risks and most benefits. Cancer screening trials also are meant to show whether early detection (finding cancer before it causes symptoms) decreases a person's chance of dying from the disease. For some types of cancer, finding and treating the disease at an early stage may result in a better chance of recovery.There is no standard or routine screening test for ovarian cancer.Screening for ovarian cancer has not been proven to decrease the death rate from the disease.Screening for ovarian cancer is under study and
Ovarian Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - Ovarian Cancer Prevention
Avoiding risk factors and increasing protective factors may help prevent cancer.Avoiding cancer risk factors may help prevent certain cancers. Risk factors include smoking, being overweight, and not getting enough exercise. Increasing protective factors such as quitting smoking, eating a healthy diet, and exercising may also help prevent some cancers. Talk to your doctor or other health care professional about how you might lower your risk of cancer.The following risk factors may increase the risk of ovarian cancer:Family history of ovarian cancerA woman whose mother or sister had ovarian cancer has an increased risk of ovarian cancer. A woman with two or more relatives with ovarian cancer also has an increased risk of ovarian cancer. Inherited riskThe risk of ovarian cancer is increased in women who have inherited certain changes in the following genes:BRCA1 or BRCA2 genes.Genes that are linked to hereditary nonpolyposis colorectal cancer (HNPCC; Lynch syndrome).Hormone replacement